| Darbepoetin use, by DOPPS country and cross-section |
| N Ptnts | Wgtd % | Total N | ||
|---|---|---|---|---|
| DOPPS Country | DOPPS Cross-section | 579 | 8.8% | 6,484 |
| All | DOPPS 2(2002) | |||
| DOPPS 3(2006) | 1,959 | 25.0% | 7,745 | |
| DOPPS 3(2007) | 2,052 | 29.8% | 6,861 | |
| AusNZ | DOPPS 2(2002) | 42 | 8.9% | 446 |
| DOPPS 3(2006) | 170 | 35.4% | 479 | |
| DOPPS 3(2007) | 134 | 32.1% | 434 | |
| Belgium | DOPPS 2(2002) | 42 | 8.5% | 506 |
| DOPPS 3(2006) | 112 | 23.0% | 487 | |
| DOPPS 3(2007) | 153 | 37.9% | 391 | |
| Canada | DOPPS 2(2002) | 32 | 5.3% | 555 |
| DOPPS 3(2006) | 240 | 45.7% | 525 | |
| DOPPS 3(2007) | 198 | 47.9% | 420 | |
| France | DOPPS 2(2002) | 78 | 17.9% | 434 |
| DOPPS 3(2006) | 239 | 47.1% | 512 | |
| DOPPS 3(2007) | 314 | 63.8% | 500 | |
| Germany | DOPPS 2(2002) | 72 | 14.4% | 496 |
| DOPPS 3(2006) | 190 | 36.5% | 518 | |
| DOPPS 3(2007) | 221 | 38.2% | 565 | |
| Italy | DOPPS 2(2002) | 50 | 10.5% | 478 |
| DOPPS 3(2006) | 167 | 35.6% | 469 | |
| DOPPS 3(2007) | 193 | 40.7% | 468 | |
| Japan | DOPPS 3(2006) | 1 | 0.1% | 1,531 |
| DOPPS 3(2007) | 2 | 0.1% | 1,549 | |
| Spain | DOPPS 2(2002) | 59 | 10.7% | 549 |
| DOPPS 3(2006) | 187 | 30.5% | 619 | |
| DOPPS 3(2007) | 200 | 38.4% | 512 | |
| Sweden | DOPPS 2(2002) | 100 | 19.7% | 508 |
| DOPPS 3(2006) | 148 | 28.5% | 516 | |
| DOPPS 3(2007) | 184 | 38.4% | 477 | |
| UK | DOPPS 2(2002) | 95 | 17.7% | 521 |
| DOPPS 3(2006) | 260 | 62.9% | 411 | |
| DOPPS 3(2007) | 227 | 70.1% | 324 | |
| US | DOPPS 2(2002) | 9 | 0.4% | 1,991 |
| DOPPS 3(2006) | 245 | 13.2% | 1,678 | |
| DOPPS 3(2007) | 226 | 17.1% | 1,221 | |
| Use in previous four months, among patients on any ESA |
Please see additional methodological information in the Data Sources and Methods section.